Starton Therapeutics Strengthens Leadership Team With Promotion Of Rod Hartwig To VP Of R&D And Manufacturing

Starton Therapeutics Inc., a clinical-stage biotechnology company focused on advancing standard-of-care therapies through proprietary continuous delivery technologies, announced the promotion of Rod Hartwig from Executive Director of Product Development to Vice President of Research and Development/Manufacturing, effective October 1, 2025. In his new role, Mr. Hartwig will join the company’s leadership team and report directly to Pedro Lichtinger, Chairman and CEO of Starton Therapeutics. This transition comes ahead of the planned retirement of Andy Rensink, Starton’s Chief Manufacturing Officer, who will retire on October 31, 2025.

Mr. Hartwig brings extensive experience in pharmaceutical development and manufacturing to his expanded role. Prior to joining Starton, where he has contributed for six years, he served for about ten years as Vice President of Operations at ProSolus, Inc., a topical and transdermal delivery system company based in Miami, Florida. In that role, he focused on the development and manufacturing of generic transdermal patches and supported the successful application and approval of an ANDA transdermal patch.

Pedro Lichtinger, Chairman and CEO, stated, “We are deeply grateful to Andy for his seven years of outstanding leadership and dedication to Starton. His contributions have played a vital role in shaping our development strategy and positioning us for long-term success. We are excited to congratulate Rod on his well-deserved promotion and are confident his experience and commitment to excellence will guide our R&D team and manufacturing to a successful future.”

Earlier in his career, Mr. Hartwig served as Vice President of Operations and Manufacturing at Azopharma Product Development Group, a Contract Development and Manufacturing Organization in Miramar, Florida. He has also contributed to the pharmaceutical industry through several publications, industry presentations, and holds numerous patents across his work at Starton, ProSolus, and Noven, where he began his career in pharmaceutical product development.